B cell-based vaccine loaded with the ligand of natural...

Details B cell-based vaccine loaded with the ligand of natural... B cell-based vaccine loaded with the ligand of natural...

2011-08-23

2011-08-23

Canella, Karen (Department: 1643)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Animal or plant cell

C424S184100, C424S204100, C424S234100

Reexamination Certificate

active

08003093

ABSTRACT:
The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with α-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor.

REFERENCES:
patent: 2006/0216316 (2006-09-01), Dhodapkar et al.
Abstract of Wheeler (Salud p'ublica de M'exico, (Jul.-Aug. 1997) 39 (4) 283-7).
Efferson et al (Anticancer research, 2005, vol. 25, pp. 715-24.
Bachman et al (Journal of Immunology, 2005, vol. 175, pp. 4677-4685.
Abstract of Kim et al (Journal of Immunology, Apr. 1, 2006, vol. 176, suppl S, p. S260).
Abstract of Ko et al (Journal of Immunology, Apr. 1, 2006, vol. 176, suppl S, p. S260).
Fujii et al (Journal of Immunological Methods, 2003, vol. 272, pp. 147-159).
Singh et al (Journal of Immunology, 1999, vol. 163, pp. 2373-2377).
Chang et al (Journal of Experimental Medicine, May 2005, vol. 201, pp. 1503-1517).
Lang et al (Immunology, 2004, vol. 112, pp. 386-396).
Brandsma et al (Journal. of Virology, 2004, vol. 78, pp. 116-123).
Wang et al (Journal of Immunology, 2004, vol. 173, pp. 6357-6365).
Hans, J.J. et al., “Potent expansion of human nautral killer T cells using α-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15,” J. Immun. Methods., 247, 61-72, (2001).
Zeytin He, et al., “Combination of a Poxvirus-Based Vaccine with a Cyclooxygenase-2 Inhibitor (Celecoxib) Elicits Antitumor immunity and Long-Term Survival in CEA.Tg/MIN Mice,” Cancer Res., 64(10):3668-3678, (2004).
Reilly RT, et al., “The Collboration of Both Humoral and Cellular HER-2
eu-targeted Immune Responses is Required for the Complete Eradication of HER-2
eu-expressing Tumors,” Cancer Res., 61(3):880-883, (2001).

Affiliated with

Also associated with

Rating

B cell-based vaccine loaded with the ligand of natural... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with B cell-based vaccine loaded with the ligand of natural..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and B cell-based vaccine loaded with the ligand of natural... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2768797